EVENTS · EW
PEERS
EARNINGS
Edwards Lifesciences Corporation is a medical technology company focused on structural heart disease and critical care monitoring. Edwards Lifesciences develops and markets transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, and surgical structural heart products used to repair or replace damaged heart valves. Its portfolio supports minimally invasive procedures designed for patients with advanced cardiovascular conditions, while its monitoring technologies help clinicians assess heart function and fluid status in surgical and intensive care settings. The company serves hospitals, heart centers, and healthcare professionals across major international markets, with products distributed in the United States, Europe, Japan, and other regions. Headquartered in Irvine, California, and founded in 1958, Edwards Lifesciences is recognized for its role in advancing specialized therapies for complex heart disease.
Truist upgraded Edwards Lifesciences after strong clinical trial results
Wed| Series | 1W | 1M |
|---|---|---|
| EW | +8.3% | +14.9% |
| Peers | +5.1% | +13.4% |
| Sector · Health Care | +5.7% | +13.6% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 74 | 76 |
| QUARTER | EPS EST | EPS ACTUAL | EPS SURPRISE | REACTION |
|---|---|---|---|---|
| Q3 FY2026 | 0.73 | 0.80 | +9.59% | — |
| Q2 FY2026 | 0.76 | 0.78 | +2.27% | −1.42% |
| Q1 FY2026 | 0.75 | 0.78 | +4.17% | +5.56% |
| Q4 FY2025 | 0.64 | 0.58 | −8.85% | +2.96% |
| Q3 FY2025 | 0.61 | 0.67 | +9.62% | −1.23% |
| Series | 1W | 1M |
|---|---|---|
| EW | +8.3% | +14.9% |
| Peers | +5.1% | +13.4% |
| Sector · Health Care | +5.7% | +13.6% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 74 | 76 |
